Companies · Other Health Care

Vibrynt, INc

Redwood City · Other Health Care

Diligence memoA one-page analyst read on Vibrynt, INc — recommendation, valuation, rhythm, risks.
$14.3M
Total raised · real
2
Rounds
0.2×
Latest step-up
Top 21%
Sector rank · raised
Series A
Latest stage · inferred · Fri May 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time)

Vibrynt, INc looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.48× the median modeled value of Series A Other Health Care companies in 2010–2012 (199 peers) — value vs value, same stage and era.
Dormant
  • Last raise 14.1 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

Vibrynt, INc is one of 5376 Other Health Care companies tracked from Redwood City. By capital raised it ranks in the upper tier (ahead of 80% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeries A · 2011-05-02 Raised $12M (real) Modeled valuation $232M (est)$12M$232MSeries A2011Series A · 2012-05-18 Raised $2.8M (real) Modeled valuation $55M (est)$2.8M$55MSeries A2012+$2.8MCumulative $14M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$11.5M · 2011
Series A extension$2.8M · 2012

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$55.5M
Base estimate est.
$3.5M
Conservative case
$301.7M
Upside case
$12.5M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Series A · modeled $232.1M · 2011-05-022011Series A · modeled $55.5M · 2012-05-182012
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
52%
Survival probability
28% low · 71% high
1.43×/yr
Annual markup
1.80×/yr upside case
6.0 yr
Elapsed time used
14.1 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
13 mo
Avg between rounds
$13.6M/yr
Capital velocity
15.2 yr
On record since
2011
First round
2
Rounds on file
How it compares to the market

Benchmarked against 5376 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 5.9× above median
This company$14.3M
Sector median$2.4M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.5× of median
This company$2.8M
Sector median$5.6M
Modeled value — vs sector median (estimate, all stages) 2.5× above median
This company$55.5M
Sector median$22.1M

Raised more than 80% of sector peers (real $). Modeled value above 69% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #159 of 199.

This companyCohort peer
$10.0M$100.0M$1.0B$10.0M$100.0MCapital raised (log)Barrx Medical Inc · Series A Raised $15.0M · modeled $302.7M (est)Cas Medical Systems Inc · Series A Raised $16.9M · modeled $302.7M (est)Icad Inc · Series A Raised $27.1M · modeled $302.7M (est)Cardiosolutions Inc · Series A Raised $18.5M · modeled $300.3M (est)Ophthonix Inc · Series A Raised $24.7M · modeled $283.4M (est)FMS Watertown, LLC · Series A Raised $13.7M · modeled $277.2M (est)Flowood Vascular Access, LLC · Series A Raised $13.7M · modeled $277.2M (est)Cardiovascular Systems Inc · Series A Raised $58.5M · modeled $272.4M (est)HemaSource Holdings LLC · Series A Raised $13.5M · modeled $272.2M (est)OMNI Home Health Acquisition, LLC · Series A Raised $12.6M · modeled $253.2M (est)Integrated Sleep Holdings Inc · Series A Raised $12.4M · modeled $249.9M (est)AngioScore Inc. · Series A Raised $12.0M · modeled $242.2M (est)Vibrynt, INc (this company) Raised $14.3M · modeled $55.5M (est)Vibrynt, INc
CompanyStageRaised · realValue · estvs peer med.
Barrx Medical IncSeries A$15.0M$302.7M2.60×
Cas Medical Systems IncSeries A$16.9M$302.7M2.60×
Icad IncSeries A$27.1M$302.7M2.60×
Cardiosolutions IncSeries A$18.5M$300.3M2.58×
Ophthonix IncSeries A$24.7M$283.4M2.44×
FMS Watertown, LLCSeries A$13.7M$277.2M2.38×
Flowood Vascular Access, LLCSeries A$13.7M$277.2M2.38×
Cardiovascular Systems IncSeries A$58.5M$272.4M2.34×
HemaSource Holdings LLCSeries A$13.5M$272.2M2.34×
OMNI Home Health Acquisition, LLCSeries A$12.6M$253.2M2.18×
Integrated Sleep Holdings IncSeries A$12.4M$249.9M2.15×
AngioScore Inc.Series A$12.0M$242.2M2.08×
Vibrynt, INc this companySeries A$14.3M$55.5M0.48×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$11.5M2011-05-02$52.3M$232.1M90%
Series A$2.8M2012-05-18$12.5M$55.5M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$11.5M2011-05-02
    • First recorded raise — entered as Series A.
  2. Series A$2.8M2012-05-18
    • Raised 13 mo later, in step with the ~14 mo sector norm.
    • Round 4.2× smaller than the prior — bridge or down round.
Intelligence
2013 ~Q2
Modeled next raise · ~13mo cadence
$2.8M
Modeled next size est.range $2.8M$4.4M
0.2×
Last step-up
$13.6M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Robert Anderson23 other2011-05
Ryan Drant23 other2012-05
John Nehra10 other2012-05
Joshua Makower9 other2012-05
ROBERT CROCE6 other2012-05
Robert W. Croce6 other2011-05
Heather Preston5 other2012-05
Douglas Roeder4 other2012-05
Beverly Huss3 other2011-05
Joshua W. Makower3 other2011-05
Ryan W. Drant3 other2011-05
John W. Nehra1 other2011-05
Kenneth Lin1 other2012-05
Douglas W. Roeder2011-05
Keith W. Grossman2011-05
Kenneth W. Lin2011-05
Vicente Trelles2012-05
Vincente W. Trelles2011-05
Registry & provenance

Vibrynt, INc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1400152
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Neotract IncOther Health CareSeries C$117.5M$293.0Mnetwork8 shared operators · same sector
ExploraMed NC7, Inc.Other Health CareSeries C$181.5M$751.6Mnetwork6 shared operators · same sector
Moximed, IncOther Health CareSeries C$187.8M$499.3Mnetwork7 shared operators · same sector
ExploraMed IV, L.L.C.OtherSeries A$6.6M$99.9Mnetwork5 shared operators · same stage
Nuelle, Inc.Other Health CareSeries B$36.6M$156.2Mnetwork3 shared operators · same sector
Patientkeeper IncOther Health CareSeries A$23.2M$18.2Mnetwork2 shared operators · same sector · same stage
PolyRemedy IncOther Health CareSeries A$13.7M$10.9Mnetwork1 shared operator · same sector · same stage
BridgePoint Medical, Inc.Other Health CareSeries A$16.2M$183.6Mnetwork1 shared operator · same sector · same stage
Frequently asked
How much funding has Vibrynt, INc raised?
Vibrynt, INc has raised approximately $14.3M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Vibrynt, INc's estimated valuation?
Provath's modeled valuation for Vibrynt, INc is approximately $55.5M (modeled range $3.5M–$301.7M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Vibrynt, INc at?
Vibrynt, INc's latest modeled financing stage is Series A. Its most recent recorded round closed around Fri May 18.
What does Vibrynt, INc do and where is it based?
Vibrynt, INc operates in the Other Health Care sector, based in Redwood City.
Explore related

See where Vibrynt, INc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Vibrynt, INc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.